SAN DIEGO, July 23, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ...
Preliminary results of a first-in-human phase 1b (aCCeleR8-001) study of S-531011, a humanized anti-CCR8 monoclonal antibody, in patients with advanced solid tumors. Efficacy and safety of ozuriftamab ...
BioAtla, Inc. has promising pipeline projects, including masked antibodies and ADCs targeting AXL and ROR2, showing early efficacy and potential for improved cancer treatments. Financially, BioAtla ...
Western blots can often be overlooked as a commonplace research tool in proteomics, but there have been continual updates and progress in the technical development of the western blot and the list of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results